CICS-1、SPM-011、［18F］FBPAを用いたCICS、住友重機械工業、ステラファーマの委託による

基本情報

NCT ID

NCT06603987

ステータス

招待制

試験のフェーズ

第1/第2相

試験タイプ

介入

目標被験者数

30

治験依頼者名

Stella Pharma Corporation

概要

To evaluate the safety and efficacy of Boron Neutron Capture Therapy (BNCT) in patients with recurrent thoracic solid tumors that are difficult to treat with standard radiation therapy or drug therapy and are unresectable. With "lung," "heart," "liver," "spinal cord," and "esophagus" as common risk organs in the treatment plan for BNCT using therapeutic CT to evaluate the safety and efficacy of BNCT in patients with unresectable and recurrent thoracic solid tumors which are difficult to treat with standard radiation and drug therapy. To evaluate the safety of ［18F］FBPA synthesized with MPS200FBPA. In addition, the usefulness of ［18F］FBPA-PET testing to determine the appropriateness of performing BNCT will be evaluated in an exploratory manner.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)